Back to search
FDAFDA · Food and drugs·Recall number D-0270-2021

Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL), 2 mL Single-Dose Vial, Rx Only, Distributed by: Areva Pharmaceuticals, Inc., Gerogetown, IN 47122, Made in India, NDC 59923-714-02.

Published March 3, 2021 · Recall initiated: November 19, 2020

Summary

FDA records drug Class II recall D-0270-2021, published March 3, 2021 and initiated November 19, 2020. Recalling firm: Areva Pharmaceuticals Inc; Status: Terminated; Reported quantity: 3287 vials; Lot: Lot 7S10022A, Exp Jan-21. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the investigation conclusions.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Areva Pharmaceuticals Inc
Distributor
Nationwide in the USA
Lot
Lot 7S10022A, Exp Jan-21
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL), 2 mL Single-Dose Vial, Rx Only, Distributed by: Areva Pharmaceuticals, Inc., Gerogetown, IN 47122, Made in India, NDC 59923-714-02. recalled?

Yes. FDA published recall D-0270-2021 on March 3, 2021. Reported hazard: CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the investigation conclusions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter